Hematology, Oncology & BMT Annual Report :: Nationwide Children's Hospital

Hematology, Oncology and Blood and Marrow Transplant (BMT) 2014-2015 Annual Report

View the Nationwide Children's Hospital 2014-2015 Annual Report.

The Division of Hematology/Oncology/Blood and Marrow Transplantation (BMT) at Nationwide Children’s Hospital treats patients with any one of a full array of blood disorders, cancers, immunodeficiency disorders, bone marrow failure syndromes and inherited metabolic storage diseases. Our clinical team oversees the comprehensive evaluation, multidisciplinary diagnosis, treatment and long-term management of children, adolescents and young adults with blood disorders and cancer as well as other diseases treated by cellular therapies.

In addition to clinical care, through our integrated programs with The Research Institute’s Center for Childhood Cancer and Blood Diseases at Nationwide Children’s and the Biopathology Center at Nationwide Children’s, we seek to transform the way patients with cancer and blood disorders are cared for by fully integrating research, cutting-edge therapies and multidisciplinary teams.

Innovative Programs and Services

The Division of Hematology, Oncology and Blood and Marrow Transplant (BMT) is committed to advancing both basic and clinical research. The division works hand-in-hand with the Center for Childhood Cancer and Blood Diseases at Nationwide Children’s to expand the understanding of childhood cancer and to improve strategies for its diagnosis and treatment. We offer the latest treatment options and new clinical trials to our patients. The division is expanding in the area of experimental therapeutics, offering patients more access to phase I and phase II studies, including both industry-sponsored and investigator-initiated trials. Total inpatient admissions and outpatient visits have been growing in recent years, and we now exceed 13,000 annually, distinguishing the division as one of the largest in the United States.

A prime example of our outstanding programs is our brain and spinal tumor program, with a vision for improving the treatment and outcomes of children and adolescents with central nervous system tumors. Jonathan L. Finlay, MB, ChB, FRCP, joined our team this year as the medical director of the Neuro-Oncology Program at Nationwide Children’s. Dr. Finlay is a professor of pediatrics at The Ohio State University College of Medicine and an internationally recognized authority in the management of childhood brain tumors. He has led our efforts to create a unique, stand-alone multidisciplinary neurooncology tumor board, neuro-oncology pathology rounds, international virtual tumor board and consultative service in real-time, and a fourth year neuro-oncology fellowship training program.

Dr. Finlay pioneered the treatment of pediatric brain tumors with high-dose chemotherapy and autologous blood cell transplantation to improve outcomes for patient with recurrent malignant brain tumors. He has a special interest in minimizing the negative longterm neurocognitive consequences of radiation therapy. Dr. Finlay’s clinical approach has been studied in a series of three prospective multinational “Head Start” clinical trials, the fourth of which will be coordinated through Nationwide Children’s National Experimental Therapeutics (NEXT) Consortium. NEXT is a collaborative research model for investigator-initiated studies that contribute to the early development of promising new therapies for childhood cancer and blood disorders.

National Biobanking Leadership

The Biopathology Center (BPC) aims to excel in long-term acquisition and storage of cancer-related tissue specimens and associated data in support of cutting-edge research. Led by Nilsa Ramirez, MD, and Julie Gastier-Foster, PhD, the BPC is primarily government-funded and collaborates with multiple research organizations to establish a significant infrastructure to support excellence in tissue banking, testing and distribution.

The BCP houses several National Cancer Institute-sponsored cancer biobanks, including the Children’s Oncology Group biobank, the largest pediatric specimen bank in the nation.

Grants Awarded


Center for Childhood Cancer and Blood Diseases

Cam, Hakan
Targeting STAT3 to prevent metastasis in pediatric sarcomas
Hyundai Foundation
Chandler, Dawn
Using TSUNAMI in a sensitized mouse to generate an intermediate SMA model
National Institutes of Health 
National Institute of Neurological Disorders and Stroke 
Coordinately regulated alternative splicing in DNA damage and cancer
National Institutes of Health 
National Cancer Institute
Insulin receptor splicing in response to hypoxia and drug resistance
OSU Comprehensive Cancer Center
Coordinately regulated alternative splicing in DNA damage and cancer
National Institutes of Health 
National Cancer Institute 
Research Enhancement Assistance Program (REAP) for 2015
OSU Comprehensive Cancer Center
Exploratory Evaluation of Study Drug Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Department of Defense
Experimental therapeutics targeting the NF2 kinome: an integrated rational approach
Children's Brain Tumor Foundation
Dominguez, Catherine
SMA mouse models: splicing manipulation and therapeutic SMN replacement
National Institutes of Health 
National Institute of Neurological Disorders and Stroke 
Houghton, Peter
Pediatric Preclinical Testing Program
National Institutes of Health
National Cancer Institute
Johnson, Robert
Determining if EphB2 expression is required for mouse ependymoma tumor growth:  EphB2 as a novel target for treating ependymoma
The Childhood Brain Tumor Foundation
Lin, Jiayuh
A novel STAT3-selective inhibitor for medulloblastoma therapy
National Institutes of Health
National Institute of Neurological Disorders and Stroke
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy
National Institutes of Health 
National Cancer Institute 
Combination of a MEK and STAT3 inhibitor for KRas mutant pancreatic and colon cancer therapy
The Ohio State University
OSU Comprehensive Cancer Center
Research Enhancement & Assistance Program (REAP)
OSU Comprehensive Cancer Center
Shah, Nilay
Elucidation of Neuroblastoma Tumorigenesis using Zebrafish Models of Disease
Alex's Lemonade Stand
Wang, Pin-Yi
Enhancing Oncolytic Herpes Virotherapy Through Directed Evolution Strategy
Elsa U. Pardee Foundation
Wang, Ruoning
Metabolic dysregulation and therapeutic intervention in asthma
National Institutes of Health (NIH)
Metabolic reprogramming and modulation of adaptive immunity in tumour microenvironment
The V Foundation for Cancer Research
Targeting GABA Metabolic Pathway in Cancer
Industry Sponsor
Metabolic reprogramming and therapeutic intervention in rhabdomyosarcoma
The Ohio State University
OSU Comprehensive Cancer Center

Hematology/Oncology/Blood and Marrow Transplant

Auletta, Jeff
Industry Sponsor
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
National Marrow Donor Program
St. Baldrick's Foundation
Industry Study
Industry Sponsor
Cripe, Timothy
Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors
Food and Drug Administration
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors
Children's Hospital Medical Center Cincinnati
National Institutes of Health 
CendR peptide-mediated enhancement of systemic oncolytic herpes virotherapy
National Institutes of Health 
National Cancer Institute 
Preclinical Studies of Tropomyosin Isoform Inhibitors
The Kids Cancer Project
Strategies to enhance SEPREHVIR therapy by combining PD-1 checkpoint receptor blockade
Industry Sponsor
The Study of the Tumor Microenviroment in Pediatric Solid Cancers
Alex's Lemonade Stand
Acidic phospholipid-selective treatment for neuroblastoma
University of Cincinnati 
National Institutes of Health
Dennis, Robyn
Phase 1b/2 Study of study drugs in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
Industry Sponsor
A Phase 2, Multicenter, Single-arm Study of study drug in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) of B-cell Origin
Industry Sponsor
A retrospective non-interventional study of remission rates and survival among pediatric patients with relapsed or refractory b-cell presursor Acute Lymphoblastic Leukemia (ALL)
Children's Hospital of Los Angeles
Dunn, Amy
Patient and Family Support Group for Hemophilia Clinic
Hemophilia Foundation of Michigan
Cascade Hemophilia Consortium
Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of study drug in previously treated pediatric patients with severe hemophilia A
Industry Sponsor
Biological Variation in Hemophilia (Emory Study)
Emory University
National Institutes of Health (NIH)
Industry Study in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A
Industry Sponsor
Industry Study in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Industry Sponsor
Public health surveilance for the prevention of complications of bleeding and clotting disorders. (CDC)
Hemophilia Foundation of Michigan
Centers for Disease Control and Prevention
Radionuclide Synovectomy/Synoviorthesis (RS) in Patients With Bleeding Disorders: Pilot Processes
American Thrombosis and Hemostasis Network
Hemophilia A – Industry Study
Industry Sponsor
Hemophilia Alliance Foundation
The Alliance Pharmacy
Hemophilia Inhibitor Research Study Phase III Protocol
Indiana Hemophilia and Thrombosis Center
My Life, Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository
American Thrombosis and Hemostasis Network
Industry Sponsor
Kumar, Riten
Multicentre, open-label, active-controlled, randomized study in children with acute venous thromboembolis 
Industry Sponsor.
Leonard, Jeffrey
The Park-Reeves Syringomyelia Research Consortium (PR1891)
Washington University
O’Brien, Sarah
Comprehensive Sickle Cell Treatment Center
Ohio Department of Health
Research Institute at Nationwide Children's Hospital Infrastructure Award
St. Baldrick's Foundation
Olshefski, Randal
Eliminating CLABSI's Ambulatory Patients
Johns Hopkins University
Agency for Healthcare Research and Quality (AHRQ)
Ranalli, Mark
A Dose Confirmation and Pharmacokinetic Study of Asparec IV infusion in Children and Young Adults with ALL/LBL Following Hypersensitivity to Pegaspargase (Oncaspar)
Childrens Hospital of Philadelphia
Industry Sponsor
A Phase 1/2 Study in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Childrens Hospital of Philadelphia
Industry Sponsor
COG NCORP Research Base 
Childrens Hospital of Philadelphia
National Institutes of Health (NIH)
Roberts, Ryan
Manipulating mechanisms of lung tropism to prevent osteosarcoma metastasis  
American Association for Cancer Research
Rose, Melissa
A Single Arm, Open-label, Long-term Efficacy and Safety Study of Study Drug 
Industry Sponsor
Pyruvate Kinase Deficiency (PKD) Natural History Study
Boston Children's Hospital
Industry Sponsor
Setty, Bhuvana
A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination with Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center
Utilizing the Collaborative Peds TCC Infrastructure Towards Molecular Discovery of Novel Translocations and the Exonic Mutational Landscape in Esthesioneuroblastomas and Small Cell Osteosarcoma
H. Lee Moffitt Cancer Center
A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center
Personalized Medicine: Pediatric Total Cancer Care Protocol
H. Lee Moffitt Cancer Center
Streby, Keri
Oncolytic Viroradiotherapy - A Novel Approach to Relapsed/Recurrent Neuroblastoma
H. Lee Moffitt Cancer Center
Pediatric Cancer Research Foundation
A Phase II Preventative Trial of study drug in Patients with High Risk Neuroblastoma in Remission.
Spectrum Health System
Helen DeVos Children’s Hospital
Thompson, Joel
Effects of Chemotherapy on Immune Function in Pediatric Oncology Patients
Rally Foundation
Woods, Gary
Hemophilia Clinical Fellowship Program
Industry Sponsor

Hematology, Oncology and BMT Faculty

Timothy P. Cripe, MD, PhD
Division Chief

Randal S. Olshefski, MD
Section Chief

View Our Faculty »

selected hematology, oncology and bmt publications

Compas B, Desjardina L, Rodriguez E, Dunn M, Bemis H, Vannatta K, Young-Saleme T, Snyder S, Gerhardt C. Children and adolescents coping with cancer: self- and parent reports of coping and anxiety/depression. Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association. 2014 Aug; 33(8):853-61.

Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP. Going back to class I: MCH and immunotherapies for childhood cancer. Pediatric Blood and Cancer. 2015 Apr;62(4):571-6.

Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE. Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome. Journal of the American Society of Nephrology: JASN. 2015 Apr 8. [Epub ahead of print].

Khamees D, Kilma J, O’Brien SH. Population screening for von Willebrand’s disease in adolescents with heavy menstrual bleeding. The Journal of Pediatrics. 2015 Jan;166(1):195-7.

O’Brien SH, Kulkarni R, Wallace A, Hamblin F, Burr S, Goldenberg NA. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. Journal of Thrombosis and Haemostasis: JTH. 2014 Nov;12(11):1822-25.

View Team Publications »

Center for Childhood Cancer and Blood Diseases

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000